Intrinsiqq
Pharma Equity Group A/S logo

Pharma Equity Group A/S Financials

PEG.XCSE

Compare

All currency values in kr millions unless otherwise noted

Scroll

Income Statement
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenuekr 0kr 0kr 0kr 0kr 0
Cost of Revenuekr 0kr 0kr 0kr 0–
Gross Profitkr 0kr 0kr 0kr 0–
General & Administrativekr 12kr 12–––
Research & Developmentkr 5kr 9–––
Total Operating Expenseskr 17kr 21kr 25kr 11–
Operating Income-kr 17-kr 21-kr 25-kr 11kr 0
Non-Operating
Net Interest Expense-kr 3-kr 5-kr 2-kr 0-kr 1
Other Non-Operating Income (Expense)-kr 7-kr 16–––
EBT (Earnings Before Tax)-kr 26-kr 42–––
Income Tax Expense-kr 1-kr 2-kr 2-kr 2kr 0
Earnings from Continuing Ops-kr 25-kr 41–––
Net Income
Net Income-kr 25-kr 41-kr 24-kr 9kr 5
Per Share Data
Revenue Per Sharekr 0.00kr 0.00kr 0.00kr 0.00kr 0.00
EPS (Basic)-kr 0.02-kr 0.02-kr 0.02-kr 0.01kr 0.10
EPS (Diluted)-kr 0.02-kr 0.02-kr 0.02-kr 0.01kr 0.10
Shares Outstanding1.27B2.03B1.22B944.4M56.8M

Pharma Equity Group A/S (PEG.XCSE) financials: revenue, profit and margins

Pharma Equity Group A/S (PEG.XCSE) generated about DKK 0.00 in revenue and -DKK 25 million in net income over the trailing twelve months. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Pharma Equity Group A/S's (PEG.XCSE) revenue?+

Pharma Equity Group A/S generated about DKK 0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Pharma Equity Group A/S profitable?+

Pharma Equity Group A/S reported about -DKK 25 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

Peers

Biotechnology · Pick stocks to compare with PEG.XCSE

CompareIntrinsic value
BIOPOR.XCSEBioPorto A/S
€0.11-4.31%36
VIRO.XCSEViroGates A/S
€0.80-13.11%10
STENO.XCSEStenocare A/S
€0.07-3.34%30
GUBRA.XCSEGubra A/S
€34.90-2.73%98
BAVA.XCSEBavarian Nordic A/S
€33.58+2.88%84
GN.XCSEGN Store Nord A/S
No recent price3
DEMANT.XCSEDemant A/S
kr 344.10-1.83%71
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing PEG.XCSE

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.